Neuroscience

Congress Materials - Psych Congress 2026

2026 Psych Congress |Sep 15-19 | New Orleans, LA

This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: A Pooled Analysis of Efficacy Across Patient-Reported Depression Symptoms

Michael E. Thase, Ibrahim Turkoz, Brian Curcio, Kristin R. Dorsey, Hank Zhang, Manish K. Jha

Congress Materials - Psych Congress 2026

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: A Pooled Analysis of Efficacy Across Patient-Reported Depression Symptoms

Adjunctive Lumateperone 42 mg Treatment in Major Depressive Disorder: Efficacy Across Patient-Reported Depression Symptoms

Assessment of Lumateperone Partial Agonist Activity at Presynaptic Dopamine D2 Autoreceptors: Reversal of Haloperidol-induced Tyrosine Hydroxylase Phosphorylation in Mouse Striatum

Association of Major Depressive Disorder With Insomnia Symptoms With Healthcare Resource Use and Cardiovascular and Metabolic Conditions – Analysis of the National Health & Nutrition Examination Survey

Association of Schizophrenia-Related Hospitalization Before Long-Acting Injectable Antipsychotic Initiation and Outcomes Among Young Dual Eligibles

Change in the Mean Total Score of the Patient Health Questionnaire-9 among Bipolar Depression Patients treated with Lumateperone in the United States: An Electronic Health Records Study

Efficacy of Adjunctive Lumateperone in Patients With Major Depressive Disorder: A Pooled Post Hoc Analysis of Patients With Clinical Features Associated With a More Challenging Disease Course

Efficacy of Esketamine Nasal Spray Monotherapy for Treatment-Resistant Depression: Post Hoc Analysis by Baseline Disease Severity and Prior Treatment

Esketamine Nasal Spray on Anhedonia and Functional Outcomes: Findings from the Ventura Real-World Evidence Study

Incidence of Cardiometabolic Events Associated With Major Depressive Disorder With Major Depressive Disorder With and Without Insomnia Symptoms: A Real-World Evidence Study

Incremental Healthcare Resource Utilization and Costs Associated With Depression Severity Measured by the Patient Health Questionnaire-9

Lumateperone 42 mg in Major Depressive Disorder: Demographic and Clinical Subgroups Efficacy Analysis in a Phase 3 Randomized Placebo-Controlled Trial

Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials

Lumateperone Treatment of Manic Episodes With or Without Mixed Features in Bipolar I Disorder: Results From a Double-Blind, Placebo-Controlled, Randomized, Phase 3 Trial

Metabolic Profile of Adjunctive Lumateperone 42 mg in Major Depressive Disorder: A Pooled Analysis of 2 Randomized, Placebo-Controlled Trials

Montgomery-Åsberg Depression Rating Scale Anhedonia Factor Score Following Esketamine Nasal Spray Monotherapy in Adult Patients With Treatment-Resistant Depression: A Post Hoc Analysis

Patient and Healthcare Practitioner Treatment Preferences for Treatment-Resistant Depression

Patient characteristics, diagnostic history, and treatment journeys among patients with newly diagnosed bipolar disorder

Perspectives of Nurse Practitioners and Physician Assistants/Associates on Presenting Long-Acting Injectables to Adults with Schizophrenia: A Delphi Panel Study

Preservation of Cardiometabolic Health During Adjunctive Lumateperone Treatment in Major Depressive Disorder (MDD): A Post Hoc Analysis

Rapid and Sustained Remission with Esketamine Nasal Spray in Patients with Treatment-Resistant Depression: Overview of Remission Rates from Six Clinical Trials

Real-world Lumateperone Dosing Patterns and Treatment Duration in Bipolar Depression

Total Cost per Remitter of Lumateperone Versus Cariprazine for the Treatment of Major Depressive Disorder in the United States

Treatment Satisfaction, Quality of Life, Satisfaction with Participation in Social Roles, and Caregiver Burden with Paliperidone Palmitate 3-Month and 6-Month Long-Acting Injectables

Understanding Insomnia Management in Major Depressive Disorder Through Patient–Provider Discourse

Connect with us

Connect with us